TY - JOUR
T1 - Single cell mutant selection for metabolic engineering of actinomycetes
AU - Akhgari, Amir
AU - Baral, Bikash
AU - Koroleva, Arina
AU - Siitonen, Vilja
AU - Fewer, David P.
AU - Melançon, Charles E.
AU - Rahkila, Jani
AU - Metsä-Ketelä, Mikko
N1 - Funding Information:
The financial support from the Jane and Aatos Erkko foundation to M.M.-K., Novo Nordisk Foundation (Grant number NNF21OC0068849 ) to M.M.-K. the Finnish Cultural Foundation to A.A. and the Turku University Foundation to B.B. is acknowledged. The authors would like to thank Wubin Gao, Džesika Pozlevičiūtė and Sazia Rahman for assistance in experimental analyses. We thank Tiina Pessa-Morikawa for assistance in flow sorting performed at the HiLife Flow Cytometry Viikki Sorting Unit, University of Helsinki.
Funding Information:
The financial support from the Jane and Aatos Erkko foundation to M.M.-K. Novo Nordisk Foundation (Grant number NNF21OC0068849) to M.M.-K. the Finnish Cultural Foundation to A.A. and the Turku University Foundation to B.B. is acknowledged. The authors would like to thank Wubin Gao, Džesika Pozlevičiūtė and Sazia Rahman for assistance in experimental analyses. We thank Tiina Pessa-Morikawa for assistance in flow sorting performed at the HiLife Flow Cytometry Viikki Sorting Unit, University of Helsinki.
Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Actinomycetes are important producers of pharmaceuticals and industrial enzymes. However, wild type strains require laborious development prior to industrial usage. Here we present a generally applicable reporter-guided metabolic engineering tool based on random mutagenesis, selective pressure, and single-cell sorting. We developed fluorescence-activated cell sorting (FACS) methodology capable of reproducibly identifying high-performing individual cells from a mutant population directly from liquid cultures. Actinomycetes are an important source of catabolic enzymes, where product yields determine industrial viability. We demonstrate 5-fold yield improvement with an industrial cholesterol oxidase ChoD producer Streptomyces lavendulae to 20.4 U g−1 in three rounds. Strain development is traditionally followed by production medium optimization, which is a time-consuming multi-parameter problem that may require hard to source ingredients. Ultra-high throughput screening allowed us to circumvent medium optimization and we identified high ChoD yield production strains directly from mutant libraries grown under preset culture conditions. Genome-mining based drug discovery is a promising source of bioactive compounds, which is complicated by the observation that target metabolic pathways may be silent under laboratory conditions. We demonstrate our technology for drug discovery by activating a silent mutaxanthene metabolic pathway in Amycolatopsis. We apply the method for industrial strain development and increase mutaxanthene yields 9-fold to 99 mg l−1 in a second round of mutant selection. In summary, the ability to screen tens of millions of mutants in a single cell format offers broad applicability for metabolic engineering of actinomycetes for activation of silent metabolic pathways and to increase yields of proteins and natural products.
AB - Actinomycetes are important producers of pharmaceuticals and industrial enzymes. However, wild type strains require laborious development prior to industrial usage. Here we present a generally applicable reporter-guided metabolic engineering tool based on random mutagenesis, selective pressure, and single-cell sorting. We developed fluorescence-activated cell sorting (FACS) methodology capable of reproducibly identifying high-performing individual cells from a mutant population directly from liquid cultures. Actinomycetes are an important source of catabolic enzymes, where product yields determine industrial viability. We demonstrate 5-fold yield improvement with an industrial cholesterol oxidase ChoD producer Streptomyces lavendulae to 20.4 U g−1 in three rounds. Strain development is traditionally followed by production medium optimization, which is a time-consuming multi-parameter problem that may require hard to source ingredients. Ultra-high throughput screening allowed us to circumvent medium optimization and we identified high ChoD yield production strains directly from mutant libraries grown under preset culture conditions. Genome-mining based drug discovery is a promising source of bioactive compounds, which is complicated by the observation that target metabolic pathways may be silent under laboratory conditions. We demonstrate our technology for drug discovery by activating a silent mutaxanthene metabolic pathway in Amycolatopsis. We apply the method for industrial strain development and increase mutaxanthene yields 9-fold to 99 mg l−1 in a second round of mutant selection. In summary, the ability to screen tens of millions of mutants in a single cell format offers broad applicability for metabolic engineering of actinomycetes for activation of silent metabolic pathways and to increase yields of proteins and natural products.
KW - Amycolatopsis
KW - Fluorescence-activated cell sorting
KW - Polyketide
KW - Protein production
KW - Streptomyces
UR - http://www.scopus.com/inward/record.url?scp=85134428449&partnerID=8YFLogxK
U2 - 10.1016/j.ymben.2022.07.002
DO - 10.1016/j.ymben.2022.07.002
M3 - Article
C2 - 35809806
AN - SCOPUS:85134428449
SN - 1096-7176
VL - 73
SP - 124
EP - 133
JO - Metabolic Engineering
JF - Metabolic Engineering
ER -